Re-evaluation of oral contraceptive classifications

Bruce R. Carr, Paul C. MacDonald

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Classification of combination oral contraceptives (OCs) by 'generation' - typically based on the time of introduction of new compounds is - problematic. The estrogen and progestin components may be present in differing dosages, and their interaction may therefore vary from one formulation to another. In addition, assigning the progestin component itself to a particular generation does not account [or the unique characteristics of individual progestins within that group. These issues can be clarified by understanding the evolution of combination OCs in relation to dosage changes and by differentiating the pharmacologic profiles of individual progestins, particularly norgestimate, desogestrel, and gestodene. Although all sex steroids have the same basic structure, relatively minor structural modifications can cause dramatic alterations in biochemical activity. Progestational activity is the desired pharmacologic effect of progestins used in OCs, whereas androgenic activity, which increases the potential for adverse metabolic and physical side effects, is undesired. In vitro assays of the ability of various OC progestins to bind progestin and androgen receptors suggest that the androgen/progestin (A/P) binding ratio - a measure of progestin selectivity - is more favorable for norgestimate than for levonorgestrel, gestodene, or desogestrel. In vivo measurements of interactions between various progestins and human sex hormone binding globulin (SHBG) support the concept that generational classification of OC progestins is misleading. These compounds also differ clinically, as exemplified by differential effects on lipoprotein metabolism. In summary, progestins exhibit individually unique biochemical and clinical properties.

Original languageEnglish (US)
Pages (from-to)133-144
Number of pages12
JournalInternational Journal of Fertility and Women's Medicine
Volume42
Issue numberSUPPL. 1
StatePublished - 1997

Fingerprint

Progestins
Oral Contraceptives
Desogestrel
Levonorgestrel
Sex Hormone-Binding Globulin
Androgen Receptors
Progesterone Receptors
Androgens
Lipoproteins
Estrogens
Steroids

Keywords

  • Androgenicity
  • Estrogen
  • Nomenclature
  • Oral contraceptives
  • Progestin

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Re-evaluation of oral contraceptive classifications. / Carr, Bruce R.; MacDonald, Paul C.

In: International Journal of Fertility and Women's Medicine, Vol. 42, No. SUPPL. 1, 1997, p. 133-144.

Research output: Contribution to journalArticle

@article{acdb33c80d6340d299483397f564ce42,
title = "Re-evaluation of oral contraceptive classifications",
abstract = "Classification of combination oral contraceptives (OCs) by 'generation' - typically based on the time of introduction of new compounds is - problematic. The estrogen and progestin components may be present in differing dosages, and their interaction may therefore vary from one formulation to another. In addition, assigning the progestin component itself to a particular generation does not account [or the unique characteristics of individual progestins within that group. These issues can be clarified by understanding the evolution of combination OCs in relation to dosage changes and by differentiating the pharmacologic profiles of individual progestins, particularly norgestimate, desogestrel, and gestodene. Although all sex steroids have the same basic structure, relatively minor structural modifications can cause dramatic alterations in biochemical activity. Progestational activity is the desired pharmacologic effect of progestins used in OCs, whereas androgenic activity, which increases the potential for adverse metabolic and physical side effects, is undesired. In vitro assays of the ability of various OC progestins to bind progestin and androgen receptors suggest that the androgen/progestin (A/P) binding ratio - a measure of progestin selectivity - is more favorable for norgestimate than for levonorgestrel, gestodene, or desogestrel. In vivo measurements of interactions between various progestins and human sex hormone binding globulin (SHBG) support the concept that generational classification of OC progestins is misleading. These compounds also differ clinically, as exemplified by differential effects on lipoprotein metabolism. In summary, progestins exhibit individually unique biochemical and clinical properties.",
keywords = "Androgenicity, Estrogen, Nomenclature, Oral contraceptives, Progestin",
author = "Carr, {Bruce R.} and MacDonald, {Paul C.}",
year = "1997",
language = "English (US)",
volume = "42",
pages = "133--144",
journal = "International Journal of Fertility and Women's Medicine",
issn = "1534-892X",
publisher = "Medical Science Publishing International Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Re-evaluation of oral contraceptive classifications

AU - Carr, Bruce R.

AU - MacDonald, Paul C.

PY - 1997

Y1 - 1997

N2 - Classification of combination oral contraceptives (OCs) by 'generation' - typically based on the time of introduction of new compounds is - problematic. The estrogen and progestin components may be present in differing dosages, and their interaction may therefore vary from one formulation to another. In addition, assigning the progestin component itself to a particular generation does not account [or the unique characteristics of individual progestins within that group. These issues can be clarified by understanding the evolution of combination OCs in relation to dosage changes and by differentiating the pharmacologic profiles of individual progestins, particularly norgestimate, desogestrel, and gestodene. Although all sex steroids have the same basic structure, relatively minor structural modifications can cause dramatic alterations in biochemical activity. Progestational activity is the desired pharmacologic effect of progestins used in OCs, whereas androgenic activity, which increases the potential for adverse metabolic and physical side effects, is undesired. In vitro assays of the ability of various OC progestins to bind progestin and androgen receptors suggest that the androgen/progestin (A/P) binding ratio - a measure of progestin selectivity - is more favorable for norgestimate than for levonorgestrel, gestodene, or desogestrel. In vivo measurements of interactions between various progestins and human sex hormone binding globulin (SHBG) support the concept that generational classification of OC progestins is misleading. These compounds also differ clinically, as exemplified by differential effects on lipoprotein metabolism. In summary, progestins exhibit individually unique biochemical and clinical properties.

AB - Classification of combination oral contraceptives (OCs) by 'generation' - typically based on the time of introduction of new compounds is - problematic. The estrogen and progestin components may be present in differing dosages, and their interaction may therefore vary from one formulation to another. In addition, assigning the progestin component itself to a particular generation does not account [or the unique characteristics of individual progestins within that group. These issues can be clarified by understanding the evolution of combination OCs in relation to dosage changes and by differentiating the pharmacologic profiles of individual progestins, particularly norgestimate, desogestrel, and gestodene. Although all sex steroids have the same basic structure, relatively minor structural modifications can cause dramatic alterations in biochemical activity. Progestational activity is the desired pharmacologic effect of progestins used in OCs, whereas androgenic activity, which increases the potential for adverse metabolic and physical side effects, is undesired. In vitro assays of the ability of various OC progestins to bind progestin and androgen receptors suggest that the androgen/progestin (A/P) binding ratio - a measure of progestin selectivity - is more favorable for norgestimate than for levonorgestrel, gestodene, or desogestrel. In vivo measurements of interactions between various progestins and human sex hormone binding globulin (SHBG) support the concept that generational classification of OC progestins is misleading. These compounds also differ clinically, as exemplified by differential effects on lipoprotein metabolism. In summary, progestins exhibit individually unique biochemical and clinical properties.

KW - Androgenicity

KW - Estrogen

KW - Nomenclature

KW - Oral contraceptives

KW - Progestin

UR - http://www.scopus.com/inward/record.url?scp=0031406408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031406408&partnerID=8YFLogxK

M3 - Article

C2 - 9168373

AN - SCOPUS:0031406408

VL - 42

SP - 133

EP - 144

JO - International Journal of Fertility and Women's Medicine

JF - International Journal of Fertility and Women's Medicine

SN - 1534-892X

IS - SUPPL. 1

ER -